• Bacitracin (B1670): Technical Protocols for Antibacterial Re

  2026-08-04

  Bacitracin (B1670) is a peptide antibiotic designed to inhibit bacterial cell wall and peptidoglycan synthesis in gram-positive and gram-negative bacteria, making it suitable for laboratory-based antibacterial research. It is not intended for diagnostic or clinical use, and must be handled in controlled workflows with attention to protocol and storage requirements.

• Radicicol: Hsp90 Inhibitor Workflows for Cell Fate & Inflamm

  2026-08-04

  Radicicol from APExBIO unlocks precise modulation of cell differentiation, apoptosis, and inflammatory pathways through robust Hsp90 inhibition. This guide details experimental workflows, troubleshooting, and advanced applications, bridging bench discovery with translational impact.

• Tumor-Targeted PAD4 Inhibition via m-PBA: Mechanistic Advanc

  2026-08-03

  The referenced study introduces a meta-phenylboronic acid-modified PAD4 inhibitor (Compound 5i TFA) that achieves highly selective tumor targeting and robust inhibition of the PAD4-H3cit-NETs pathway. These findings support the development of safer, tumor-focused immunomodulatory strategies for inhibiting metastasis and modulating the tumor immune microenvironment.

• 17-AAG (Tanespimycin): Optimizing HSP90 Inhibition in Cancer

  2026-08-03

  17-AAG (Tanespimycin) empowers researchers to precisely disrupt HSP90 chaperone networks, enabling targeted oncogenic protein degradation and apoptosis induction in cancer models. This article bridges recent mechanistic advances with practical workflows, providing actionable steps and troubleshooting strategies for maximizing experimental reliability and translational impact.

• CD40 and STING Compete for TRAF2 to Activate B Cells in ESCC

  2026-08-02

  This study uncovers a novel mechanism in which CD40 and STING competitively bind to TRAF2, driving IRF4-mediated B cell activation within tertiary lymphoid structures in esophageal squamous cell carcinoma (ESCC). The findings deepen our understanding of tumor immunity, highlighting new avenues for biomarker discovery and therapeutic strategies targeting the STING–CD40–TRAF2–IRF4 axis.

• HDAC Inhibition Reverses EBV-Induced Plasticity in NPC Cells

  2026-08-01

  This study demonstrates how HDAC inhibition can reverse Epstein-Barr virus (EBV)-driven dedifferentiation in nasopharyngeal carcinoma (NPC) by restoring CEBPA expression. The findings establish a mechanistic link between viral oncogenesis, epigenetic regulation, and cellular plasticity, suggesting differentiation therapy as a promising strategy in solid tumors.

• Pomalidomide (CC-4047): Precision Tools for Myeloma Research

  2026-07-31

  This thought-leadership article explores how Pomalidomide (CC-4047) is reshaping translational research in multiple myeloma and related hematological malignancies. Integrating mechanistic insight, experimental protocol guidance, and the latest mutational landscape findings, it provides strategic direction for researchers aiming to design robust studies that address drug resistance and tumor heterogeneity. With context from recent literature and APExBIO product innovation, this piece offers a forward-looking vision for precision oncology.

• Dual-Action Kinase Inhibitors Accelerate p38α Dephosphorylat

  2026-07-31

  This study reveals that certain kinase inhibitors, including STI571 hydrochloride, promote dephosphorylation of p38α MAP kinase by stabilizing a phosphatase-accessible conformation. These findings provide a mechanistic framework for dual-action inhibition and suggest new strategies for enhancing specificity in kinase-targeted research.

• Inducing Mammalian Embryonic Dormancy via mTOR Inhibition Pr

  2026-07-30

  This article reviews a protocol that enables reversible induction of a diapause-like dormant state in mammalian embryonic cells using pharmacological mTOR inhibition. The approach offers a noninvasive, scalable alternative to traditional surgical methods, facilitating investigation of dormancy mechanisms and potential advances in developmental biology and reproductive technology.

• CLCC1 Enables Membrane Fusion in Herpesvirus Nuclear Egress

  2026-07-30

  A recent study identifies the host chloride channel CLCC1 as an essential mediator of membrane fusion during herpesvirus nuclear egress, a critical step for viral maturation. These findings clarify a longstanding gap in herpesvirus biology and suggest new avenues for antiviral research.

• Cyclic di-GMP: Mastering Biofilm and Immune Modulation Workf

  2026-07-29

  Cyclic di-GMP is redefining research precision in both bacterial biofilm regulation and STING-driven immune modulation. This guide delivers actionable experimental strategies, troubleshooting insights, and evidence-based protocol enhancements, anchored by the latest mechanistic discoveries.

• 17-AAG (Tanespimycin): Optimizing HSP90 Inhibition Workflows

  2026-07-29

  Harness the precision of 17-AAG (Tanespimycin) for reliable HSP90 chaperone inhibition in cancer research. This article provides actionable protocols, advanced troubleshooting, and cross-domain insights for maximizing experimental success with APExBIO’s trusted reagent.

• Lenalidomide (CC-5013): Translational Strategies in Myeloma

  2026-07-28

  This thought-leadership article examines the evolving role of Lenalidomide (CC-5013) as an immune system activation agent and angiogenesis inhibitor in multiple myeloma research. Integrating mechanistic insights, recent epigenetic findings, and workflow guidance, the piece offers translational researchers a roadmap for maximizing therapeutic impact and experimental reproducibility, while contextualizing APExBIO’s product in the landscape of next-generation immuno-oncology.

• Tumor-Targeted PAD4 Inhibitors Disrupt NETs to Suppress Meta

  2026-07-28

  The referenced study introduces meta-phenylboronic acid (m-PBA)-modified PAD4 inhibitors, exemplified by Compound 5i TFA, achieving highly selective tumor targeting and potent inhibition of the PAD4–H3cit–NETs pathway in neutrophils. This approach demonstrates significant antitumor efficacy and precise modulation of the tumor immune microenvironment, providing a new paradigm for selective cancer therapy.

• Epacadostat (INCB024360): Applied Protocols for IDO1 Inhibit

  2026-07-27

  Epacadostat (INCB024360) is redefining preclinical immuno-oncology workflows by enabling precise, nanomolar-scale inhibition of IDO1-driven immune suppression. This guide details evidence-backed workflows, troubleshooting strategies, and the latest advances in whole-blood immunometabolic assays for robust, reproducible investigation.

8364 records 3/558 page Previous Next 12345 下5页 Last page